RT Journal Article
SR Electronic
T1 Real-life effectiveness of beclomethasone diproprionate/formoterol extra-fine combination in adult patients with persistent asthma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p3956
VO 38
IS Suppl 55
A1 Guy G. Brusselle
A1 Paul Van Den Brande
A1 Rudy Peché
A1 Bart Fonteyn
A1 Domenico Iacono
A1 Marianne Blockmans
A1 Jacques Bruhwyler
A1 Wim Hollanders
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p3956.abstract
AB Background: Efficacy and safety of extra-fine beclomethasone dipropionate 100 μg/formoterol 6 μg pMDI (BDP/F) in adult patients with moderate-to-severe persistent asthma has been demonstrated in double-blind randomized controlled clinical trials.Objective: To assess real-life effectiveness of BDP/F on asthma control.Methods: Non-interventional, prospective, open-label, multicentre study in Belgium from December 2008 till December 2010. Patients were enrolled by pneumologists and general practitioners (GPs). Visit 1 (Day 0): demographic and baseline asthma control data collection, initiation of BDP/F treatment; Visit 2 (Day 61-240) and Visit 3 (Day 241-420): evaluation of asthma control by patients (Juniper ACQ7) and investigators (GINA asthma control score), assessment of BDP/F safety/tolerability.Results: 619 patients were enrolled: mean age 48±16.9 years, 54% female, 22.8% smokers, mean FEV1% pred 78.6±20.0%. At visit 3 the mean daily beclomethasone dose was 266±127μg.View this table:Table 1. Evolution of ACQ7 and GINA asthma control scoresSimilar improvements in asthma control, evaluated as patient-reported ACQ7 score or physician-rated GINA asthma control score, were observed in patients recruited by pneumologists and by GPs. Treatment-related non-serious adverse drug reactions were reported in 16 patients (2.6%).Conclusion: The results of this study demonstrate the real-life effectiveness of extrafine BDP/F in adult patients with moderate-to-severe persistent asthma.